Skip to main content
SpringerLink
Log in

Is There a Role for Raloxifene and Tamoxifen for the Prevention of Breast Cancer?

  • Chapter
  • First Online:
Trends in Breast Cancer Prevention

  • 654 Accesses

Abstract

Breast cancer is the leading oncologic disease in women in the world and is the second leading cause of death in Western women. A major advance in breast cancer chemoprevention in healthy high risk women occurred with the pioneering studies of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene. Tamoxifen, the first targeted therapy for the treatment of breast cancer approved by the Food and Drug Administration (FDA), was subsequently successful in significantly reducing the incidence of breast cancer in high risk women. Nevertheless, tamoxifen has some adverse effects in the uterus. Raloxifene, that is also FDA approved for breast cancer prevention in high risk postmenopausal women and separately for osteoporosis, has a better safety profile than tamoxifen. In this chapter we will describe the history, the current role and deficiencies of tamoxifen and raloxifene in the prevention of breast cancer. The potential of other SERMs and new approaches to hormone replacement to improve women’s health but to reduce the risk of breast cancer are illustrated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. CancerResearchUK.org. Worldwide cancer incidence statistics. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/world/incidence/#By.

  2. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer. 1936;27:217–28.

    Article  Google Scholar 

  3. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–13.

    Article  CAS  PubMed  Google Scholar 

  4. Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 2006;147 Suppl 1:S269–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985;2:282.

    Article  CAS  PubMed  Google Scholar 

  6. Jordan VC. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat. 1983;3(Suppl):S73–86.

    Article  PubMed  Google Scholar 

  7. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 1987;47:4020–4.

    CAS  PubMed  Google Scholar 

  8. Harper MJ, Walpole AL. Mode of action of I.C.I. 46,474 in preventing implantation in rats. J Endocrinol. 1967;37:83–92.

    Article  CAS  PubMed  Google Scholar 

  9. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat. 1987;10:31–5.

    Article  CAS  PubMed  Google Scholar 

  10. Gottardis MM, Robinson SP, Satyaswaroop PG, et al. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988;48:812–5.

    CAS  PubMed  Google Scholar 

  11. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.

    Article  CAS  PubMed  Google Scholar 

  12. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990;82:1327–32.

    Article  CAS  PubMed  Google Scholar 

  13. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991;115:860–4.

    Article  CAS  PubMed  Google Scholar 

  14. Kumar V, Green S, Stack G, et al. Functional domains of the human estrogen receptor. Cell. 1987;51:941–51.

    Article  CAS  PubMed  Google Scholar 

  15. Koide A, Zhao C, Naganuma M, et al. Identification of regions within the F domain of the human estrogen receptor alpha that are important for modulating transactivation and protein-protein interactions. Mol Endocrinol. 2007;21:829–42.

    Article  CAS  PubMed  Google Scholar 

  16. Montano MM, Muller V, Trobaugh A, et al. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol. 1995;9:814–25.

    CAS  PubMed  Google Scholar 

  17. Schwartz JA, Zhong L, Deighton-Collins S, et al. Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydroxytamoxifen. J Biol Chem. 2002;277:13202–9.

    Article  CAS  PubMed  Google Scholar 

  18. Yang J, Singleton DW, Shaughnessy EA, et al. The F-domain of estrogen receptor-alpha inhibits ligand induced receptor dimerization. Mol Cell Endocrinol. 2008;295:94–100.

    Article  CAS  PubMed  Google Scholar 

  19. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753–8.

    Article  CAS  PubMed  Google Scholar 

  20. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95:927–37.

    Article  CAS  PubMed  Google Scholar 

  21. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev. 1984;36:245–76.

    CAS  PubMed  Google Scholar 

  22. Jordan VC. Laboratory models of breast cancer to aid the elucidation of antiestrogen action. J Lab Clin Med. 1987;109:267–77.

    CAS  PubMed  Google Scholar 

  23. Levenson AS, Jordan VC. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 1998;58:1872–5.

    CAS  PubMed  Google Scholar 

  24. Liu H, Lee ES, Deb Los Reyes A, et al. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res. 2001;61:3632–9.

    CAS  PubMed  Google Scholar 

  25. Liu H, Park WC, Bentrem DJ, et al. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J Biol Chem. 2002;277:9189–98.

    Article  CAS  PubMed  Google Scholar 

  26. MacGregor Schafer J, Liu H, Bentrem DJ, et al. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res. 2000;60:5097–105.

    CAS  PubMed  Google Scholar 

  27. MacGregor Schafer J, Liu H, Levenson AS, et al. Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol. 2001;78:41–50.

    Article  CAS  PubMed  Google Scholar 

  28. Powles TJ, Hardy JR, Ashley SE, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989;60:126–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Powles TJ, Jones AL, Ashley SE, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat. 1994;31:73–82.

    Article  CAS  PubMed  Google Scholar 

  30. Jones AL, Powles TJ, Treleaven JG, et al. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer. 1992;66:744–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78–84.

    CAS  PubMed  Google Scholar 

  32. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352:93–7.

    Article  CAS  PubMed  Google Scholar 

  33. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817–24.

    Article  CAS  PubMed  Google Scholar 

  34. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;93:63–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637–45.

    Article  CAS  PubMed  Google Scholar 

  36. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189–97.

    Article  CAS  PubMed  Google Scholar 

  37. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001;65:125–34.

    Article  CAS  PubMed  Google Scholar 

  38. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751–61.

    Article  CAS  PubMed  Google Scholar 

  39. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.

    Article  CAS  PubMed  Google Scholar 

  40. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.

    Article  CAS  PubMed  Google Scholar 

  41. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). 2010;3:696–706.

    Article  CAS  Google Scholar 

  42. Jordan VC, Allen KE. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer. 1980;16:239–51.

    Article  CAS  PubMed  Google Scholar 

  43. Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441–52.

    Article  CAS  PubMed  Google Scholar 

  44. Jordan VC. Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst. 2014;106.

    Google Scholar 

  45. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000;6:2028–36.

    CAS  PubMed  Google Scholar 

  46. Haddow A, Watkinson JM, Paterson E, et al. Influence of synthetic oestrogens on advanced malignant disease. Br Med J. 1944;2:393–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Haddow A, David A. Karnofsky memorial lecture. Thoughts on chemical therapy. Cancer. 1970;26:737–54.

    Article  CAS  PubMed  Google Scholar 

  48. Song RX, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 2001;93:1714–23.

    Article  CAS  PubMed  Google Scholar 

  49. Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005;97:1746–59.

    Article  CAS  PubMed  Google Scholar 

  50. Liu H, Lee ES, Gajdos C, et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst. 2003;95:1586–97.

    Article  CAS  PubMed  Google Scholar 

  51. Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer. 2015;22:R1–31.

    Article  CAS  PubMed  Google Scholar 

  52. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526–32.

    Article  CAS  PubMed  Google Scholar 

  53. Schmidt C. The breast cancer chemoprevention debate. J Natl Cancer Inst. 2011;103:1646–7.

    Article  PubMed  Google Scholar 

  54. Waters EA, McNeel TS, Stevens WM, et al. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012;134:875–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28:3090–5.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Donnelly LS, Evans DG, Wiseman J, et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer. 2014;110:1681–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Dragan YP, Fahey S, Street K, et al. Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res Treat. 1994;31:11–25.

    Article  CAS  PubMed  Google Scholar 

  58. Greaves P, Goonetilleke R, Nunn G, et al. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 1993;53:3919–24.

    CAS  PubMed  Google Scholar 

  59. Hard GC, Iatropoulos MJ, Jordan K, et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 1993;53:4534–41.

    CAS  PubMed  Google Scholar 

  60. Williams GM, Iatropoulos MJ, Djordjevic MV, et al. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 1993;14:315–7.

    Article  CAS  PubMed  Google Scholar 

  61. Han XL, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 1992;52:1360–3.

    CAS  PubMed  Google Scholar 

  62. Mani C, Pearce R, Parkinson A, et al. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 1994;15:2715–20.

    Article  CAS  PubMed  Google Scholar 

  63. Martin EA, Rich KJ, White IN, et al. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis. 1995;16:1651–4.

    Article  CAS  PubMed  Google Scholar 

  64. Pathak DN, Bodell WJ. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis. 1994;15:529–32.

    Article  CAS  PubMed  Google Scholar 

  65. White IN, de Matteis F, Davies A, et al. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis. 1992;13:2197–203.

    Article  CAS  PubMed  Google Scholar 

  66. Nichols HB, DeRoo LA, Scharf DR, et al. Risk-benefit profiles of women using tamoxifen for chemoprevention. J Natl Cancer Inst. 2015;107:354.

    Article  PubMed  Google Scholar 

  67. Roetzheim RG, Lee JH, Fulp W, et al. Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast. 2015;24:51–6.

    Article  PubMed  Google Scholar 

  68. Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res (Phila). 2011;4:1360–5.

    Article  CAS  Google Scholar 

  69. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 1990;50:4177–89.

    CAS  PubMed  Google Scholar 

  70. Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology. 1998;139:2068–76.

    Article  CAS  PubMed  Google Scholar 

  71. Maeda T, Ke HZ, Simmons H, et al. Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies. Clin Calcium. 2004;14:85–93.

    PubMed  Google Scholar 

  72. Cummings S, Eastell R, Ensrud K. The effects of lasofoxifene on fractures and breast cancer: 3 year results from the PEARL trial. J Bone Miner Res. 2008;23:S81.

    Google Scholar 

  73. Davidson M, Moffett A, Welty F, et al. Extraskeletal effects of lasofoxifene on postmenopausal women. J Bone Miner Res. 2005;20:S173.

    Google Scholar 

  74. Gennari L. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Expert Opin Pharmacother. 2009;10:2209–20.

    Article  CAS  PubMed  Google Scholar 

  75. McClung M, Siris E, Cummings S. Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD. J Bone Miner Res. 2005;20:F429.

    Google Scholar 

  76. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause. 2006;13:377–86.

    Article  PubMed  Google Scholar 

  77. Moffett AH, Ettinger M, Bolognese M, et al. Lasofoxifene, a next generation SERM, is effective in preventing loss of BMD and reducing LDL-C in postmenopausal women. J Bone Miner Res. 2004;19:F426.

    Article  Google Scholar 

  78. LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010;102:1706–15.

    Article  CAS  PubMed  Google Scholar 

  79. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362:686–96.

    Article  CAS  PubMed  Google Scholar 

  80. Freddie CT, Larsen SS, Bartholomaeussen M, et al. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. Mol Cell Endocrinol. 2004;219:27–36.

    Article  CAS  PubMed  Google Scholar 

  81. Cummings SR, McClung M, Reginster JY, et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011;26:397–404.

    Article  CAS  PubMed  Google Scholar 

  82. Bolognese M, Krege JH, Utian WH, et al. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. J Clin Endocrinol Metab. 2009;94:2284–9.

    Article  CAS  PubMed  Google Scholar 

  83. Kendler DL, Palacios S, Cox DA, et al. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis. Osteoporos Int. 2012;23:1091–101.

    Article  CAS  PubMed  Google Scholar 

  84. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–34.

    Article  CAS  PubMed  Google Scholar 

  85. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009;16:1109–15.

    Article  PubMed  Google Scholar 

  86. Jordan VC, Bain RR, Brown RR, et al. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res. 1983;43:1446–50.

    CAS  PubMed  Google Scholar 

  87. Qu Q, Harkonen PL, Vaananen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem. 1999;73:500–7.

    Article  CAS  PubMed  Google Scholar 

  88. DeGregorio MW, Wurz GT, Taras TL, et al. Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol. 2000;56:469–75.

    Article  CAS  PubMed  Google Scholar 

  89. Komi J, Lankinen KS, Harkonen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause. 2005;12:202–9.

    Article  PubMed  Google Scholar 

  90. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001;77:271–9.

    Article  CAS  PubMed  Google Scholar 

  91. Sweeney EE, Fan P, Jordan VC. Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women’s health initiative study. Cancer Res. 2014;74:7060–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13:476–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Jordan VC, Ford LG. Paradoxical clinical effect of estrogen on breast cancer risk: a “new” biology of estrogen-induced apoptosis. Cancer Prev Res (Phila). 2011;4:633–7.

    Article  CAS  Google Scholar 

  94. Ariazi EA, Cunliffe HE, Lewis-Wambi JS, et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A. 2011;108:18879–86.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Obiorah IE, Fan P, Jordan VC. Breast cancer cell apoptosis with phytoestrogens is dependent on an estrogen-deprived state. Cancer Prev Res (Phila). 2014;7:939–49.

    Article  CAS  Google Scholar 

  96. Obiorah I, Jordan VC. Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause. 2013;20:372–82.

    PubMed  PubMed Central  Google Scholar 

  97. Robinson SP, Koch R, Jordan VC. In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo. Cancer Res. 1988;48:784–7.

    CAS  PubMed  Google Scholar 

  98. Lonard DM, O’Malley BW. The expanding cosmos of nuclear receptor coactivators. Cell. 2006;125:411–4.

    Article  CAS  PubMed  Google Scholar 

  99. O’Malley BW. Molecular biology. Little molecules with big goals. Science. 2006;313:1749–50.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Susan G. Komen for the Cure Foundation (award number SAC100009), and the National Institutes of Health MD Anderson’s Cancer Center Support Grant, CA016672.

Author information

Authors and Affiliations

  1. Department of Breast Medical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

    Philipp Y. Maximov Ph.D. & V. Craig Jordan O.B.E., Ph.D., D.Sc.,

Authors
  1. Philipp Y. Maximov Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Craig Jordan O.B.E., Ph.D., D.Sc.,
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Craig Jordan O.B.E., Ph.D., D.Sc., .

Editor information

Editors and Affiliations

  1. The Irma H. Russo, MD, Breast Cancer Research Laboratory, Fox Chase Cancer Center--Temple Health, Philadelphia, Pennsylvania, USA

    Jose Russo

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Maximov, P.Y., Jordan, V.C. (2016). Is There a Role for Raloxifene and Tamoxifen for the Prevention of Breast Cancer?. In: Russo, J. (eds) Trends in Breast Cancer Prevention. Springer, Cham. https://doi.org/10.1007/978-3-319-27135-4_4

Download citation

Publish with us

Policies and ethics

Search

Navigation